U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER
		ATTORNET S DOCKET NUMBER
TRANSMITTAL LETTER TO THE UNITED STATES		EISENBACH4A
DESIGNATED/ELECTED OFFICE (DO/EO/US)		U.S. APPLICATION NO. (If known, see 37 CFR 1.5)
CONCERNING A FILING UNDER 35 U.S.C. 371		10/524787
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY CLAIMED
Dam /2200 /000500	T-1 28 2002	7
PCT/US03/023503 TITLE OF INVENTION	July 28, 2003	August 16, 2002
TUMOR ASSOCIATED ANTIGEN, PEPTIDES THEREOF, AND USE OF SAME AS ANTI-		
TUMOR VACCINES		
APPLICANT(S) FOR DO/EO/US		
Lea EISENBACH et al.		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
1. [X] This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.		
2. [] This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.		
3. [X] This is an express request to begin national examination procedures (35 U.S.C. 371(f)) as soon as the application is in order for		
such purpose and the applicable requirements of 35 U.S.C. 371(c) have been complied with.  4. [] The US has been elected (Art 31).		
5. [X] A copy of the International Application as filed (35 U.S.C. 371(c)(2))		
a. [ ] is attached hereto (required only if not transmitted by the International Bureau).		
b. [X] has been communicated by the International Bureau.		
c. [ ] is not required, as the application was filed in the United States Receiving Office (RO/US).		
6. [ ] An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).		
a. [] is attached hereto.		
b. [ ] has been previously submitted under 35 U.S.C. 154(d)(4).		
7. [X] Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))		
a. [ ] are transmitted herewith (required only if not transmitted by the International Bureau).		
b. [ ] have been communicated by the International Bureau.		
c. [] have not been made; however, the time limit for making such amendments has NOT expired.		
d. [X] have not been made and will not be made.		
8. [] An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).		
9. [] An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).		
<ol> <li>[ ] An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li> </ol>		
(55 515.57 1(5)(5)).		
Items 11. to 16. below concern document(s) or information included:		
11. [X ] An Information Disclosure Statement under 37 CFR 1.97 and 1.98.		
12. [ ] An Assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.		
13. [ ] A FIRST preliminary amendment.		
14. [X ] An Application Data Sheet under 37 CFR 1.76.		
15. [ ] A substitute specification.		
16. [] A change of power of attorney and/or address letter.		
17. [ ] A computer-readable sequence form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.  18. [ ] A second copy of the published International Application under 35 U.S.C. 154(d)(4).		
19. [ ] A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4)		
20. [X ] Other items or information:		
[X ] Courtesy copy of the International Application as filed.		
<ul> <li>[X ] Courtesy copy of the first page of the International Publication (WO 2001/016643 A2).</li> <li>[X ] Formal drawings, 18 sheets, Figures 1A-19B.</li> </ul>		
[X] Paper copy only of Sequence Listing.		
[X] The application is (or will be) assigned to: Yeda Research and Development Co. Ltd. whose address is Weizmann Institute of		
Science, P.O.Box 95, 76100 Rehovot, Israel.		

DT12 Rec'd PCT/PTO 1 6 FEB 2005 U.S. APPLICATION NO. (If known, see 37 CFR 1.5) International Application No. Attorney's Docket No. PCT/US03/023503 **EISENBACH4A** CALCULATIONS PTO USE ONLY [xx] a) BASIC NATIONAL FEE (37 CFR 1.492(a)).....\$300.00 [xx] b) SEARCH FEE (37 CFR 1.492(b)) [x] US was International Searching Authority.....\$100.00 Other ISR provided to USPTO.....\$400.00 \$300.00 [xx] c) EXAMINATION FEE (37 CFR 1.492 (c)) [ ] IPEA/US gave wholly favorable IPER.....\$100.00 [x] All other situations......\$200.00 TOTAL OF ABOVE CALCULATIONS: Surcharge of \$130.00 for furnishing the oath or declaration later than [ ] 20 [ ] 30 months from the earliest claimed priority date (37 CFR 1.492(h)). TOTAL SHEETS | EXTRA SHEETS Number of each additional 50 or fraction RATE (1.492(g)) thereof (round up to a whole number) - 100 X \$250.00 **CLAIMS** Rate (1.492 (d-f)) Number Filed Number Extra **Total Claims** - 20 = X \$ 50.00 - 3 = Independent Claims X \$200.00 \$ Multiple Dependent Claims (if applicable) + \$360.00 TOTAL OF ABOVE CALCULATIONS = \$300.00 Reduction of ½ for filing by small entity, if applicable. Applicant claims small entity status. See 37 \$150.00 CFR 1.27. SUBTOTAL = \$150.00 Processing fee of \$130.00 for furnishing the English translation later than [ ] 20 [ ] 30 months from the earliest claimed priority date (37 CFR 1.492(i)). TOTAL NATIONAL FEE = \$150.00 Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property TOTAL FEES ENCLOSED = \$150.00 Amount to be: \$ refunded charged \$ Payment Method (check one only) a. [ ] A check in the amount of \$ to cover the above fees is enclosed. b. [X] Credit Card Payment Form (PTO-2038), authorizing payment in the amount of \$150.00, is attached. c. [ ] Please charge my Deposit Account No. 02-4035 in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed. Handling of Fee Deficiencies (check one only) [ ] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-4035. A duplicate copy of this sheet is enclosed. [X ] If a deficiency exists in the basic national fee set by 37 CFR 1.492(a), please charge it to Deposit Account 02-4035. At this time, no authorization is given to charge any other fees. NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.437(a) or (b)) must be filed and granted to restore the application to pending status. Direct all correspondence to the address associated with CUSTOMER NUMBER 001444, which is currently: SIGNATURE BROWDY AND NEIMARK, P.L.L.C. Roger L. Browdy 624 NINTH STREET, N.W., SUITE 300 NAME WASHINGTON, D.C. 20001 25,618 TEL: (202) 628-5197 REGISTRATION NUMBER FAX: (202) 737-3528 Date of this submission: February 16, 2005

RLB:ccw